12:00 AM
Nov 08, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IntraDose: Phase II

Among 29 evaluable patients in MATX's ongoing Phase II study, 6 patients had a complete response, with tumor reduction of...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >